Impact of lengthening script duration of inhaled corticosteroid (ICS) therapy on clinical outcomes in asthma

Lead Researcher:

Professor David Price, Professor of Primary Care Respiratory Medicine and RiRL Director

Research Team:

  • Nicolas Roche
  • Dirkje Postma
  • Richard Martin
  • Eliot Israel
  • Gene Colice
  • Rupert Jones
  • Catherine Hutton
  • Dr Arjun Jain
  • Vicky Thomas
  • Derek Skinner

Status: Active


  • Teva
  • Research in Real Life


Short Description:

The study aims at assessing the relation between prescription patterns (unchanged vs increased script duration) and (i) cumulative time covered (MPR, medication possession ratio) and (ii) clinical outcomes over a one-year outcome period, in patients receiving ICS with any script duration during the baseline year.




Final Publications

Additional Material